Posted by Michael Wonder on 02 Dec 2015

Decision to retain first-line biologic access for adalimumab in dermatology and rheumatology indications

PHARMAC

2 December 2015 - PHARMAC is pleased to announce the approval of an agreement with AbbVie Limited to reduce the price and subsidy of adalimumab (Humira and HumiraPen) and to retain the same funded access criteria that currently apply to adalimumab.

For more details, go to: http://www.pharmac.health.nz/news/notification-2015-12-02-adalimumab/

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , New Zealand